```html

Spinal Muscular Atrophy (SMA) – A Complete Patient Guide

Overview

Spinal muscular atrophy (SMA) is a rare, genetic, neurodegenerative disorder that primarily weakens the muscles used for movement, breathing, and swallowing. It is caused by a loss of motor neurons in the spinal cord and the brainstem, leading to progressive muscle atrophy and weakness.

Who it affects: SMA occurs in both males and females of all ethnicities. Because it is inherited in an autosomal recessive pattern, a child must receive a defective copy of the SMN1 gene from each parent to develop the disease.

Prevalence: Approximately 1 in 10,000 live births worldwide, with a carrier frequency of about 1 in 50 – 1 in 100 individuals (CDC, 2023).

Symptoms

The clinical picture varies widely depending on the SMA type (0‑4). Below is a comprehensive list of signs that may appear at birth, infancy, childhood, or adulthood.

Motor symptoms

• Muscle weakness: Begins proximally (shoulders, hips) and progresses to distal muscles.
• Hypotonia (floppy baby syndrome): Low muscle tone noticeable in newborns.
• Difficulty sitting, standing, or walking: Varies from mild balance problems to severe inability to bear weight.
• Gait abnormalities: Waddling, toe-walking, or “frog‑leg” stance.
• Reduced or absent reflexes (hyporeflexia).
• Joint contractures: Stiffness in elbows, knees, or hips due to prolonged weakness.

Bulbar and respiratory symptoms

• Difficulty swallowing (dysphagia): May lead to choking or aspiration.
• Speech problems: Nasal voice, slurred speech.
• Weak cough and reduced airway clearance.
• Respiratory insufficiency: Shortness of breath, especially at night; may require ventilatory support.

Other possible features

• Fatigue and easy tiring.
• Orthopedic issues (scoliosis, hip dislocation).
• Constipation (due to reduced gastrointestinal motility).
• Developmental delays related to limited mobility.

Causes and Risk Factors

Genetic cause

SMA is caused by mutations or deletions in the SMN1 (Survival Motor Neuron 1) gene located on chromosome 5q13. The resulting deficiency of SMN protein leads to motor neuron death.

A second gene, SMN2, produces a small amount of functional SMN protein. The number of SMN2 copies (typically 1‑4) modifies disease severity—more copies usually result in a milder phenotype.

Inheritance pattern

• Autosomal recessive: both parents must be carriers.
• Each pregnancy has a 25 % chance of producing an affected child, 50 % chance of a carrier, and 25 % chance of an unaffected, non‑carrier child.

Risk factors

• Family history of SMA or known carrier status.
• Consanguineous marriage (higher carrier frequency in some populations).
• Lack of prenatal carrier screening.

Diagnosis

Clinical evaluation

Neurologic examination documenting weakness pattern, reflexes, and tone is the first step. Pediatricians often notice hypotonia in newborns, prompting further work‑up.

Laboratory & genetic testing

• SMN1 deletion/sequence analysis: Detects the most common mutation (present in >95 % of cases).
• SMN2 copy number assay: Helps predict disease severity and guides treatment decisions.
• Carrier testing for parents and at‑risk siblings.

Electrodiagnostic studies

• Electromyography (EMG): Shows chronic denervation and reduced motor unit potentials.
• Nerve conduction studies: Usually normal, helping distinguish SMA from peripheral neuropathies.

Imaging

MRI of the spinal cord may be performed to rule out structural lesions; it does not diagnose SMA but can be useful in complex cases.

Newborn screening

Since 2018, all U.S. states (and many countries worldwide) have added SMA to mandatory newborn screening panels. Early detection enables treatment before irreversible motor neuron loss.

Treatment Options

While SMA is not curable, disease‑modifying therapies dramatically improve outcomes, especially when started early.

Approved disease‑modifying medications

• Nusinersen (Spinraza): An antisense oligonucleotide injected intrathecally every 4 months after a loading phase. It enhances inclusion of exon 7 in SMN2 transcripts, increasing SMN protein.
  → Improves motor function in all SMA types (FDA, 2020).
• Onasemnogene abeparvovec‑xioi (Zolgensma): A one‑time intravenous gene‑replacement therapy delivering a functional copy of SMN1 via an adeno‑associated virus vector. Approved for patients < 2 years old (and now up to 21 years in some jurisdictions).
  → Near‑normal motor milestones in many infants when treated before symptom onset.
• Risdiplam (Evrysdi): An oral small‑molecule that also modifies SMN2 splicing. Once‑daily dose, approved for patients of any age, including infants ≥ 1 month.
  → Convenient for families unable to undergo intrathecal injections.

Supportive and symptomatic care

• Respiratory support: Non‑invasive ventilation (BiPAP), cough‑assist devices, or tracheostomy with mechanical ventilation for severe respiratory weakness.
• Physical & occupational therapy: Stretching, strengthening, and positioning to prevent contractures and maintain functional independence.
• Orthopedic interventions: Scoliosis monitoring; surgical fusion if curve > 40°.
• Nutrition: Swallowing assessments, gastrostomy tube placement when dysphagia compromises caloric intake.
• Cardiac monitoring: Baseline ECG; rare cardiomyopathy has been reported.

Lifestyle modifications

• Maintain a temperature‑controlled environment (heat can worsen fatigue).
• Energy‑conserving techniques – paced activities, use of assistive devices (wheelchairs, walkers).
• Vaccinations (influenza, pneumococcal) to reduce respiratory infections.

Living with Spinal Muscular Atrophy

Daily management tips

• Establish a multidisciplinary team: Neurologist, pulmonologist, physical therapist, nutritionist, and social worker.
• Regular respiratory checks: Peak flow measurements, overnight oximetry, and timely escalation to non‑invasive ventilation.
• Positioning and skin care: Change position every 2 hours, use pressure‑relieving cushions to avoid sores.
• Exercise routine: Gentle range‑of‑motion stretches 2‑3 times daily; avoid over‑exertion.
• Assistive technology: Voice‑activated home controls, adapted keyboards, and environmental control units can enhance independence.
• Psychosocial support: Peer‑support groups (e.g., Muscular Dystrophy Association), counseling, and school accommodations.
• Medication adherence: Keep a log for intrathecal injections, oral dosing, and monitor for side effects (e.g., thrombocytopenia with nusinersen).

Family considerations

Carrier testing for siblings and future family planning (pre‑implantation genetic diagnosis, prenatal testing) can be discussed with a genetic counselor.

Prevention

Because SMA is genetic, primary prevention focuses on informed reproductive choices:

• Carrier screening: Recommended for all adults of reproductive age, especially those with a family history of SMA.
• Pre‑implantation genetic diagnosis (PGD): Allows selection of embryos without the disease‑causing SMN1 mutation.
• Prenatal testing: Chorionic villus sampling or amniocentesis can detect SMA in at‑risk pregnancies.

Newborn screening does not prevent SMA but ensures early treatment, which is the most effective “preventive” strategy against severe disability.

Complications

If SMA is left untreated or inadequately managed, several serious complications can develop:

• Respiratory failure: The leading cause of mortality; may require long‑term ventilation.
• Thoracic insufficiency syndrome: Severe scoliosis compromising lung capacity.
• Swallowing dysfunction and aspiration pneumonia.
• Joint contractures and bone density loss leading to fractures.
• Fatigue‑related falls and fractures.
• Psychosocial impact: Depression, anxiety, and reduced quality of life if supports are lacking.

When to Seek Emergency Care

References

• National Institute of Neurological Disorders and Stroke. Spinal Muscular Atrophy Fact Sheet. 2023.
• Centers for Disease Control and Prevention. Newborn Screening: Spinal Muscular Atrophy. Updated 2023.
• Mayo Clinic. Spinal muscular atrophy – Symptoms and causes. 2024.
• American Academy of Pediatrics. Guidelines for the Management of SMA. 2022.
• FDA. Approval packages for Spinraza, Zolgensma, and Evrysdi. 2020‑2024.
• World Health Organization. Genetic disorders: screening and counseling. 2021.

```